Collecting global experiences in treating metastatic prostate cancer
ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa
This study is collecting real-life experiences from men with metastatic prostate cancer to see how well different treatments work for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 534 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospital of Macerata Academic / other |
| Locations | 1 site (Province of Macerata, Macerata) |
| Trial ID | NCT06200558 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather real-world data on the treatment of patients with metastatic prostate cancer (mPCa) across three distinct groups. It focuses on patients treated with androgen deprivation therapy (ADT) combined with androgen receptor signaling inhibitors (ARSI), those receiving Lutetium-177 PSMA therapy for castration-resistant prostate cancer (CRPC), and patients treated with PARP inhibitors. The study will analyze treatment outcomes and experiences to better understand the effectiveness of these therapies in various clinical settings.
Who should consider this trial
Good fit: Ideal candidates include adult patients over 18 years old with a confirmed diagnosis of metastatic prostate cancer who have received specific treatments outlined in the study.
Not a fit: Patients without a confirmed diagnosis of prostate cancer or those not meeting the specific treatment criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights that improve treatment strategies for metastatic prostate cancer patients.
How similar studies have performed: Other studies have shown success in gathering real-world data for similar treatment approaches, indicating a promising avenue for understanding treatment effectiveness.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged \>18y * Cytological or Histologically confirmed diagnosis of PC * Histologically or radiologically confirmed diagnosis of metastatic disease and For ARON-3S ▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible) For ARON-3Lu ▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC For ARON-3GEN * HRD POSITIVE STATUS * Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide Exclusion Criteria: * Patients without histologically confirmed diagnosis of PC * Patients without histologically or radiologically confirmed metastatic disease and For ARON-3S ▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section For ARON-3Lu ▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PC For ARON-3GEN * HRD NEGATIVE STATUS * Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study
Where this trial is running
Province of Macerata, Macerata
- Ospedale di Macerata — Province of Macerata, Macerata, Italy (Recruiting)
Study contacts
- Study coordinator: Matteo Santoni
- Email: sorgentoni.giulia@gmail.com
- Phone: +39 07332573752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.